ibandronic acid has been researched along with risedronic acid in 110 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (1.82) | 18.2507 |
| 2000's | 48 (43.64) | 29.6817 |
| 2010's | 48 (43.64) | 24.3611 |
| 2020's | 12 (10.91) | 2.80 |
| Authors | Studies |
|---|---|
| Cieslak, JA; Coates, RM; Fukura, S; Koohang, A; Lea, CR; Lee, HJ; Loftus, TC; Martin, MB; Matsumura, Y; Oldfield, E; Sagami, H; Sanders, JM; Sengupta, S; Szabo, CM | 1 |
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Burzynska, A; Croft, SL; de Luca-Fradley, K; Grimley, JS; Kafarski, P; Kendrick, H; Lewis, JC; Martin, MB; Meints, GA; Oldfield, E; Olsen, JR; Sanders, JM; Van Brussel, EM | 1 |
| Burzynska, A; Gómez, AO; González-Pacanowska, D; Kafarski, P; Mao, J; Meints, GA; Oldfield, E; Sanders, JM; Van Brussel, EM | 1 |
| Burzynska, A; Chan, JM; Colantino, A; Ghosh, S; Kafarski, P; Meints, G; Morita, CT; Oldfield, E; Raker, AM; Sanders, JM; Song, Y; Wang, H | 1 |
| Araujo, FG; Chan, JM; Ling, Y; Moreno, SN; Odeh, S; Oldfield, E; Sahota, G | 1 |
| Hall, P; Hudock, MP; Leon, A; Liu, L; Morita, CT; Oldfield, E; Puan, KJ; Studer, D; Yang, Y; Yin, F | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Kavanagh, KL; Kwaasi, AA; Oppermann, U; Rogers, MJ; Russell, RG | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Axelson, J; Cao, R; Chang, SC; Chang, TH; Guo, RT; Hudock, MP; K-M Chen, C; Ko, TP; Kumar, A; Liang, PH; No, JH; Oldfield, E; Song, Y; Wang, AH; Zhang, Y | 1 |
| Cass, LM; Chang, TK; Mukkamala, D; No, JH; Oldfield, E | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Altman, RA; Borel, T; Davis, I; de Azambuja, F; Johnson, D; Liu, A; Sorrentino, JP; Udokwu, C; Yang, Y | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Fisher, JE; Reszka, AA; Rodan, GA | 1 |
| Boissier, S; Cabon, F; Clézardin, P; Colombel, M; Filleur, S; Fournier, P; Guglielmi, J | 1 |
| Hosking, DJ; Pande, I | 1 |
| Chapurlat, RD | 1 |
| McClung, M | 1 |
| Rackoff, PJ; Sebba, A | 1 |
| Jack, D | 1 |
| Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB | 1 |
| Delaney, MF | 1 |
| Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM | 1 |
| Cao, R; Goddard, A; Oldfield, E; Yin, F; Zhang, Y | 1 |
| Dawson-Hughes, B; Gass, M | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Chapurlat, RD; Delmas, PD | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Gold, DT; Safi, W; Trinh, H | 2 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Díaz-Curiel, M; Moro Alvarez, MJ | 1 |
| Malden, NJ; Pai, AY | 1 |
| Civitelli, R; Emkey, R; Strampel, W | 1 |
| Rizzoli, R | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| Hochberg, MC | 1 |
| Burge, RT; Lindsay, R; Marshall, DA; Tosteson, AN | 1 |
| Okazaki, R | 1 |
| Bilezikian, JP | 1 |
| Blumentals, WA; Cole, RE; Harris, ST; Huang, L; Silverman, SL | 1 |
| Bachmann, GA; Binkley, N; Derman, RJ; Greenwald, M; Kohles, JD; Martens, MG; Silverman, SL | 1 |
| Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Bivi, N; Bonetti, A; Clarke, I; Delneri, D; Harrison, R; Hoyle, DC; Moro, L; Ortolani, F; Quadrifoglio, F; Romanello, M; Tell, G | 1 |
| Chandra, M; Go, AS; Gordon, NP; Hui, RL; Hutchinson, M; Lathon, PV; Lo, JC; Martin, D; McCloskey, CA; O'Ryan, FS; Sanchez, G; Selby, JV; Silver, P; Staffa, JA; Willy, M; Yang, J | 1 |
| Byun, DW; Choi, WH; Chung, DJ; Chung, HY; Chung, YS; Kang, MI; Kim, GS; Kim, YK; Kwon, NH; Lee, IK; Lee, YS; Lim, SK; Min, YK; Park, IH; Park, JH; Shin, CS; Shong, MH; Yoon, HK | 1 |
| Epstein, S; Jeglitsch, M; McCloskey, E | 1 |
| Glickman, G; He, J; Hsiao, A | 1 |
| Dobbins, EK; Duvall, CA; Gates, BJ; Sonnett, TE | 1 |
| Henry, C; Jahnke, W | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Glendenning, P; Inderjeeth, CA; Lee, S | 1 |
| Aapro, MS | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Jones, G; Winzenberg, T | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Abarca, J; Campbell, HE; Martin, KE; White, TJ; Yu, J | 1 |
| Arias, M; Barros, X; Blasco, M; Campistol, JM; Cases, A; Durán, CE; Torregrosa, JV | 1 |
| Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH | 1 |
| Chen, M; Chen, Y; Chen, Z; Liu, Y; Zhu, Y | 1 |
| Yates, J | 1 |
| Airia, P; Borisova, N; Ferko, NC; Grima, DT; Thompson, MF | 1 |
| Hagino, H; Hashimoto, J; Ito, M; Mizunuma, H; Nakamura, T; Nakano, T; Tobinai, M | 1 |
| Diz, P; Feijoo, JF; García, A; Limeres, J; López-Cedrún, JL; Peñarrocha, M; Sanromán, JF | 1 |
| Ben-Aharon, I; Rizel, S; Shpilberg, O; Stemmer, SM; Sulkes, A; Vidal, L; Yerushalmi, R | 1 |
| Capaldo, A; Di Somma, C; Gimigliano, F; Iolascon, G; Menditto, E; Orlando, V | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Hviid, A; Pasternak, B; Svanström, H | 1 |
| Bolognese, MA; Bone, HG; Bonnick, S; Brown, JP; Dakin, P; Ferreira, I; Hall, J; Ho, PR; Recknor, C; Roux, C; van den Bergh, JP; Wagman, RB | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Eastell, R; McCloskey, E; Paggiosi, MA; Peel, N; Walsh, JS | 1 |
| Hagino, H; Hashimoto, J; Matsunaga, M; Nakamura, T; Tobinai, M; Yoshida, S | 1 |
| Reid, IR | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Agodoa, I; Bonnick, S; Brown, JP; Ferreira, I; Ho, PR; Palacios, S; Van den Bergh, JP | 1 |
| Campos, F; Cook, GJ; Fuster, D; Marzola, MC; Muxí, A; Ramos, A; Rubello, D; Sánchez-Escuredo, A; Tapias, A; Torregrosa, JV | 1 |
| Modi, A; Sajjan, S; Siris, ES; Steve Fan, CP | 1 |
| Eastell, R; Gossiel, F; Jacques, RM; McCloskey, EV; Naylor, KE; Paggiosi, M; Peel, NF; Walsh, JS | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Di Bonito, M; Ferretti, V; Giampà, E; Nuvoli, G; Paoletti, F; Piazzini, M; Ranieri, M; Tuveri, MA; Vinicola, V | 1 |
| Adami, S; Gatti, D; Rossini, M; Viapiana, O | 1 |
| Ju, JH; Jung, SM; Koh, JH; Kwok, SK; Lee, J; Myong, JP; Park, SH | 1 |
| Hashimoto, J; Nakamura, T; Nakano, T; Tobinai, M; Yamamoto, M; Yoshida, S | 1 |
| Hashimoto, J; Ito, M; Nakamura, T; Tobinai, M; Yoshida, S | 1 |
| Keating, GM | 1 |
| Etminan, M; Guo, M; Maberley, D; Mammo, Z; Matsubara, J | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 2 |
| Kõks, S; Laius, O; Maasalu, K; Märtson, A | 1 |
| Campbell, F; Davis, S; Gittoes, N; Goka, E; Martyn-St James, M; Rawdin, A; Sadler, S; Sanderson, J; Selby, P; Stevens, J; Stevenson, M; Strong, M; Wong, R | 1 |
| Bradburn, M; Eastell, R; Gossiel, F; McCloskey, EV; Naylor, KE; Paggiosi, MA; Peel, NFA; Walsh, JS | 1 |
| Lee, DR; Lee, J | 1 |
| Ballal, P; Duryea, J; Lu, N; Neogi, T; Ratzlaff, C; Sury, M; Zhang, Y | 1 |
| Dong, S; Hu, Y; Ke, Z; Lv, M; Shen, J; Song, L; Wu, K; Xu, K; Yuan, Y | 1 |
| Chang, YF; Hsu, JC; Hsu, YH; Li, CC; Liang, FW; Ou, HT; Peng, ZY; Wu, CH | 1 |
| Huang, J; Li, P; Li, Y; Wu, X | 1 |
| McConnell, M; Shieh, A | 1 |
| Jenal, M; Ma, N; Moshi, MR; Nicolopoulos, K; Stringer, D; Vreugdenburg, T | 2 |
| Ehrenstein, V; Kafatos, G; Neasham, D; O'Kelly, J; Pedersen, AB; Risbo, N | 1 |
| Alves, C; Batel-Marques, F; Donato, A; Mendes, D; Oliveira, T; Penedones, A | 1 |
| Chen, Y; Huang, Y; Xiao, Y | 1 |
41 review(s) available for ibandronic acid and risedronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2003 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency | 2005 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Perimenopause; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Humans; Ibandronic Acid; Motor Activity; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide; United States; Vitamin D | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Humans; Ibandronic Acid; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid | 2009 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceutical; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Male; Osteonecrosis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2009 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2011 |
Challenges in clinical patient management.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis; Risedronic Acid; Tamoxifen | 2010 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spine | 2013 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Female; Humans; Ibandronic Acid; Pamidronate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; Risk; Treatment Outcome | 2013 |
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Hip Joint; Humans; Ibandronic Acid; Injections, Subcutaneous; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency | 2014 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
Ibandronate: A Review in Japanese Patients with Osteoporosis.
Topics: Administration, Intravenous; Administration, Oral; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Japan; Lumbar Vertebrae; Osteoporosis; Risedronic Acid; Spinal Fractures | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures.
Topics: Alendronate; Bone Density Conservation Agents; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Humans; Ibandronic Acid; Imidazoles; Models, Econometric; Osteoporotic Fractures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Social Work; State Medicine; United Kingdom; Zoledronic Acid | 2016 |
Pharmacological Therapies for Osteoporosis: A Bayesian Network Meta-Analysis.
Topics: Bone Density; Bone Density Conservation Agents; Female; Hip Fractures; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2022 |
Reduced All-Cause Mortality With Bisphosphonates Among Post-Fracture Osteoporosis Patients: A Nationwide Study and Systematic Review.
Topics: Diphosphonates; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Zoledronic Acid | 2022 |
Denosumab Versus Bisphosphonates for the Prevention of the Vertebral Fractures in Men with Osteoporosis: An Updated Network Meta-Analysis.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Humans; Ibandronic Acid; Male; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Spinal Fractures; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
The clinical effectiveness of denosumab (Prolia®) in patients with hormone-sensitive cancer receiving endocrine therapy, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: a systematic review and network meta-analysis
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Hormones; Humans; Ibandronic Acid; Male; Neoplasms; Network Meta-Analysis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2023 |
Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Observational Studies as Topic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2023 |
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Humans; Ibandronic Acid; Network Meta-Analysis; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures; Treatment Outcome | 2023 |
12 trial(s) available for ibandronic acid and risedronic acid
| Article | Year |
|---|---|
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastroesophageal Reflux; Heartburn; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2009 |
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Korea; Middle Aged; Osteoporosis, Postmenopausal; Patient Preference; Peptides; Prospective Studies; Risedronic Acid | 2009 |
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphonates; Disease Progression; Etidronic Acid; Female; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Phosphates; Prospective Studies; Renal Dialysis; Risedronic Acid; Skin; Uremia | 2012 |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Japan; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Risedronic Acid; Spinal Fractures; Time Factors; Treatment Outcome | 2013 |
Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Hip Joint; Humans; Ibandronic Acid; Lower Extremity; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Upper Extremity | 2014 |
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2014 |
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Risedronic Acid; Treatment Outcome | 2015 |
Monthly ibandronate versus weekly risedronate treatment for low bone mineral density in stable renal transplant patients.
Topics: Bone Density; Diphosphonates; Female; Humans; Ibandronic Acid; Kidney Transplantation; Male; Middle Aged; Risedronic Acid; Time Factors | 2015 |
Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Premenopause; Reference Values; Risedronic Acid; Treatment Outcome | 2016 |
Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study.
Topics: Administration, Intravenous; Administration, Oral; Aged; Bone Density; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Female; Femur; Humans; Ibandronic Acid; Kidney Function Tests; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Risedronic Acid; Spinal Fractures; Vitamin D | 2016 |
Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Diphosphonates; Female; Femoral Neck Fractures; Femur Neck; Humans; Ibandronic Acid; Japan; Male; Middle Aged; Osteoporosis; Risedronic Acid; Spinal Fractures; Spine | 2017 |
Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Drug Administration Schedule; Female; Hip Joint; Humans; Ibandronic Acid; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Withholding Treatment | 2018 |
57 other study(ies) available for ibandronic acid and risedronic acid
| Article | Year |
|---|---|
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents.
Topics: Alkyl and Aryl Transferases; Antiparasitic Agents; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Models, Molecular; Organophosphates; Quantitative Structure-Activity Relationship; Recombinant Proteins | 2002 |
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Activity of bisphosphonates against Trypanosoma brucei rhodesiense.
Topics: Animals; Crystallography, X-Ray; Diphosphonates; Humans; Lethal Dose 50; Models, Molecular; Quantitative Structure-Activity Relationship; Quantum Theory; Trypanocidal Agents; Trypanosoma brucei rhodesiense; Tumor Cells, Cultured | 2002 |
3-D QSAR investigations of the inhibition of Leishmania major farnesyl pyrophosphate synthase by bisphosphonates.
Topics: Animals; Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Imidazoles; Leishmania major; Models, Molecular; Picolinic Acids; Pyridines; Quantitative Structure-Activity Relationship; Zoledronic Acid | 2003 |
Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates.
Topics: Alkyl and Aryl Transferases; Animals; Cell Division; Cell Line; Diphosphonates; Geranyltranstransferase; Humans; Leishmania major; Lymphocyte Activation; Models, Molecular; Quantitative Structure-Activity Relationship; Receptors, Antigen, T-Cell, gamma-delta; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2004 |
Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations.
Topics: Aldose-Ketose Isomerases; Alkyl and Aryl Transferases; Animals; Antiprotozoal Agents; Cell Line; Diphosphonates; Fosfomycin; Geranyltranstransferase; Humans; Mice; Models, Molecular; Multienzyme Complexes; Oxidoreductases; Quantitative Structure-Activity Relationship; Toxoplasma; Toxoplasmosis | 2005 |
Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin.
Topics: Anti-Bacterial Agents; Cluster Analysis; Diphosphonates; Drug Synergism; Escherichia coli K12; Fosfomycin; Gene Expression; Geranyltranstransferase; Models, Molecular; Oligonucleotide Array Sequence Analysis; Quantitative Structure-Activity Relationship; Terpenes | 2006 |
Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Models, Molecular; Molecular Structure; Nitrogen; Stereoisomerism; Structure-Activity Relationship; Time Factors | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation.
Topics: Antineoplastic Agents; Crystallography, X-Ray; Diphosphonates; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Farnesyltranstransferase; Humans; K562 Cells; Magnetic Resonance Spectroscopy; Models, Molecular; Quantitative Structure-Activity Relationship | 2008 |
Bisphosphonate inhibition of a Plasmodium farnesyl diphosphate synthase and a general method for predicting cell-based activity from enzyme data.
Topics: Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line, Tumor; Dictyostelium; Diphosphonates; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Leishmania donovani; Models, Chemical; Plasmodium vivax; Predictive Value of Tests | 2008 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Diflunisal Derivatives as Modulators of ACMS Decarboxylase Targeting the Tryptophan-Kynurenine Pathway.
Topics: Bacterial Proteins; Binding Sites; Biosynthetic Pathways; Carboxy-Lyases; Catalytic Domain; Crystallography, X-Ray; Diflunisal; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Kynurenine; Molecular Docking Simulation; NAD; Pseudomonas fluorescens; Structure-Activity Relationship; Tryptophan | 2021 |
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine | 1991 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Geranyltranstransferase; Hydroxymethylglutaryl CoA Reductases; Ibandronic Acid; Male; Mevalonic Acid; Osteoclasts; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelium, Vascular; Epithelial Cells; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Neovascularization, Physiologic; Orchiectomy; Osteitis Deformans; Prostate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Testosterone; Tissue Distribution; Zoledronic Acid | 2002 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
A bright future for osteoporosis treatment.
Topics: Adrenergic beta-Antagonists; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Lithium Compounds; Osteogenesis; Osteoporosis; Receptor, Cannabinoid, CB1; Risedronic Acid | 2005 |
Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.
Topics: Animals; Diphosphonates; Etidronic Acid; Geranyltranstransferase; Hydrophobic and Hydrophilic Interactions; Ibandronic Acid; Kinetics; Risedronic Acid; Static Electricity; Thermodynamics; Trypanosoma brucei brucei | 2006 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Interviews as Topic; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid; United States | 2006 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis; Osteoporosis; Risedronic Acid | 2007 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Ibandronic Acid; Markov Chains; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Risk Factors; United States | 2008 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Risk Factors | 2009 |
Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Etidronic Acid; Female; Humans; Ibandronic Acid; Longitudinal Studies; Male; Middle Aged; Osteoporosis; Patient Compliance; Retrospective Studies; Risedronic Acid | 2009 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States | 2010 |
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Movement; Diphosphonates; DNA Breaks, Double-Stranded; DNA Damage; Etidronic Acid; Gene Deletion; Humans; Ibandronic Acid; Microscopy, Confocal; Microscopy, Electron; Microtubules; Mutation; Polyisoprenyl Phosphates; Risedronic Acid; RNA Interference; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2009 |
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Sectional Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Jaw Diseases; Male; Osteonecrosis; Prevalence; Risedronic Acid; Surveys and Questionnaires; Tooth Extraction | 2010 |
A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Composite Resins; Diphosphonates; Etidronic Acid; Follow-Up Studies; Gutta-Percha; Humans; Ibandronic Acid; Middle Aged; Periapical Diseases; Radiography; Retrospective Studies; Risedronic Acid; Root Canal Filling Materials; Root Canal Preparation; Single-Blind Method; Treatment Outcome; Wound Healing | 2009 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
When do bisphosphonates make the most sense?
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States; Women's Health | 2011 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diphosphonates; Drug Costs; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Insurance Claim Review; Longitudinal Studies; Male; Managed Care Programs; Medication Adherence; Middle Aged; Osteoporosis; Regression Analysis; Retrospective Studies; Risedronic Acid; United States | 2011 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Injections, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Retrospective Studies; Risedronic Acid | 2012 |
[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].
Topics: Alendronate; Chromatography, Ion Exchange; Diphosphonates; Electrochemical Techniques; Etidronic Acid; Humans; Ibandronic Acid; Pamidronate; Risedronic Acid | 2012 |
How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
Topics: Bone Density Conservation Agents; Cost Sharing; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Markov Chains; Middle Aged; Osteoporosis; Reimbursement Mechanisms; Risedronic Acid | 2012 |
Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dental Implants; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Hypertension; Ibandronic Acid; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Thiophenes | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes | 2014 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
Gastrointestinal Events Among Patients Initiating Osteoporosis Therapy: A Retrospective Administrative Claims Database Analysis.
Topics: Administrative Claims, Healthcare; Aged; Alendronate; Databases, Factual; Diphosphonates; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; United States | 2015 |
Results of a national multicentric study on compliance to treatment with various disphosphonate formulations in patients with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid | 2015 |
Atypical Femoral Fracture in Rheumatoid Arthritis Patients Treated With Bisphosphonates: A Nested Case-Control Study.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Female; Femoral Fractures; Femur; Genu Valgum; Humans; Ibandronic Acid; Logistic Models; Lumbar Vertebrae; Middle Aged; Multivariate Analysis; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2016 |
Oral Bisphosphonates and Risk of Wet Age-Related Macular Degeneration.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Case-Control Studies; Diphosphonates; Female; Humans; Ibandronic Acid; Male; Odds Ratio; Risedronic Acid; Risk Factors; Wet Macular Degeneration | 2016 |
[Bisphosphonate use and related pharmaceutical issues II].
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Confounding Factors, Epidemiologic; Diphosphonates; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hungary; Ibandronic Acid; Imidazoles; National Health Programs; Osteoporosis; Pamidronate; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2016 |
Use of drugs against osteoporosis in the Baltic countries during 2010-2014.
Topics: Alendronate; Baltic States; Bone Density Conservation Agents; Calcium Channel Blockers; Denosumab; Diphosphonates; Drug Utilization; Ergocalciferols; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Risedronic Acid | 2016 |
Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Databases, Factual; Drug Administration Schedule; Female; Humans; Ibandronic Acid; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Republic of Korea; Retrospective Studies; Risedronic Acid | 2019 |
The relation of oral bisphosphonates to bone marrow lesion volume among women with osteoarthritis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Bone Marrow; Diphosphonates; Female; Humans; Ibandronic Acid; Longitudinal Studies; Magnetic Resonance Imaging; Middle Aged; Osteoarthritis, Knee; Propensity Score; Risedronic Acid | 2020 |
Utilization patterns and factors associated with persistence of new users of anti-osteoporosis treatment in Denmark: a population-based cohort study.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2023 |
Atypical femur fracture associated with common anti-osteoporosis drugs in FDA adverse event reporting system.
Topics: Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Femur; Humans; Ibandronic Acid; Osteoporosis; Pamidronate; Pharmaceutical Preparations; Risedronic Acid | 2023 |